REPL - Replimune Group, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Woburn,
United States
Type: Equity
REPL price evolution
REPL
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $153.36 | $76.16 | $99.31 | |
| Short term investments | $317.47 | $346.21 | $368.68 | |
| Net receivables | $2.05 | $5.37 | $4.92 | $4.29 |
| Inventory | ||||
| Total current assets | $442.63 | $480.32 | $433.67 | $479.16 |
| Long term investments | ||||
| Property, plant & equipment | $53.03 | $52.51 | $52.35 | $52.13 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $54.65 | $54.05 | $53.77 | |
| Total investments | $317.47 | $346.21 | $368.68 | |
| Total assets | $498.2 | $534.97 | $487.72 | $532.93 |
| Current liabilities | ||||
| Accounts payable | $8.41 | $0.86 | $2.58 | $3.9 |
| Deferred revenue | ||||
| Short long term debt | $3.9 | $3.88 | $3.86 | |
| Total current liabilities | $43.79 | $35.68 | $40.44 | $38.65 |
| Long term debt | $68.67 | $72.05 | $71.99 | $71.95 |
| Total noncurrent liabilities | $72.83 | $72.78 | $72.74 | |
| Total debt | $75.95 | $75.87 | $75.81 | |
| Total liabilities | $116.74 | $108.51 | $113.21 | $111.39 |
| Shareholders' equity | ||||
| Retained earnings | -$808.11 | -$755.05 | -$701.28 | -$646.21 |
| Other shareholder equity | $3.63 | $4.32 | $4.86 | $4.73 |
| Total shareholder equity | $426.45 | $374.51 | $421.54 | |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $76.16 | $148.23 | $107.58 | $184.15 |
| Short term investments | $346.21 | $436.8 | $289.71 | $293.78 |
| Net receivables | $4.92 | $2.94 | $3.06 | $2.95 |
| Inventory | ||||
| Total current assets | $433.67 | $592.6 | $403.98 | $483.75 |
| Long term investments | ||||
| Property, plant & equipment | $52.35 | $52.35 | $55.58 | $57.72 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $54.05 | $53.99 | $57.22 | $59.35 |
| Total investments | $346.21 | $436.8 | $289.71 | $293.78 |
| Total assets | $487.72 | $646.59 | $461.19 | $543.1 |
| Current liabilities | ||||
| Accounts payable | $2.58 | $5.36 | $3.73 | $2.35 |
| Deferred revenue | ||||
| Short long term debt | $3.88 | $3.76 | $3.63 | $3.46 |
| Total current liabilities | $40.44 | $33.83 | $20.76 | $14.55 |
| Long term debt | $71.99 | $57 | $29.21 | $29.82 |
| Total noncurrent liabilities | $72.78 | $57.47 | $29.21 | $29.82 |
| Total debt | $75.87 | $60.76 | $32.84 | $33.28 |
| Total liabilities | $113.21 | $91.3 | $49.96 | $44.37 |
| Shareholders' equity | ||||
| Retained earnings | -$701.28 | -$485.49 | -$311.2 | -$193.17 |
| Other shareholder equity | $4.86 | $5.73 | -$0.97 | -$0.39 |
| Total shareholder equity | $374.51 | $555.29 | $411.23 | $498.73 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $42.97 | $42.58 | $42.85 | |
| Selling, general & administrative | $14.39 | $16.18 | $13.69 | |
| Total operating expenses | $57.37 | $58.76 | $56.54 | |
| Operating income | -$57.37 | -$58.76 | -$56.54 | |
| Income from continuing operations | ||||
| EBIT | -$51.81 | -$53.19 | -$49.09 | |
| Income tax expense | -$0.07 | $0.47 | ||
| Interest expense | $1.96 | $1.95 | $1.55 | |
| Net income | ||||
| Net income | -$53.77 | -$55.08 | -$51.12 | |
| Income (for common shares) | -$53.77 | -$55.08 | -$51.12 | |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $174.96 | $126.53 | $79.55 | $56.75 |
| Selling, general & administrative | $59.81 | $50.55 | $38.77 | $23.2 |
| Total operating expenses | $234.77 | $177.08 | $118.31 | $79.95 |
| Operating income | -$234.77 | -$177.08 | -$118.31 | -$79.95 |
| Income from continuing operations | ||||
| EBIT | -$208.73 | -$169.84 | -$115.81 | -$77.81 |
| Income tax expense | $0.41 | $0.29 | ||
| Interest expense | $6.66 | $4.16 | $2.22 | $3.06 |
| Net income | ||||
| Net income | -$215.79 | -$174.28 | -$118.04 | -$80.87 |
| Income (for common shares) | -$215.79 | -$174.28 | -$118.04 | -$80.87 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$53.77 | -$55.08 | -$51.12 | |
| Operating activities | ||||
| Depreciation | $0.74 | $0.7 | $0.68 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.47 | $7.92 | $8.24 | |
| Total cash flows from operations | -$49.17 | -$46.17 | -$47.12 | |
| Investing activities | ||||
| Capital expenditures | -$1.67 | -$1.74 | -$1.72 | |
| Investments | $31.43 | $24.94 | $55.67 | |
| Total cash flows from investing | $30.22 | $29.77 | $23.2 | $53.96 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $48.27 | $0 | -$0 | |
| Net borrowings | -$0.13 | -$0.13 | $14.87 | |
| Total cash flows from financing | $96.6 | $96.64 | -$0.13 | $14.87 |
| Effect of exchange rate | $0.03 | -$0.04 | -$0.06 | -$0.03 |
| Change in cash and equivalents | $39.04 | $77.2 | -$23.15 | $21.68 |
| (in millions $) | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$215.79 | -$174.28 | -$118.04 | -$80.87 |
| Operating activities | ||||
| Depreciation | $2.65 | $2.45 | $2.15 | $1.71 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $34.13 | $28.13 | $24.25 | $11.79 |
| Total cash flows from operations | -$185.47 | -$128.05 | -$82.18 | -$61.39 |
| Investing activities | ||||
| Capital expenditures | -$5.66 | -$2.27 | -$2.34 | -$2.39 |
| Investments | $102.86 | -$140.23 | $0.53 | -$186.38 |
| Total cash flows from investing | $97.2 | -$142.5 | -$1.81 | -$188.78 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.76 | $283.51 | $6.86 | $383.5 |
| Net borrowings | $14.52 | $27.79 | -$0.26 | -$11.04 |
| Total cash flows from financing | $16.28 | $311.3 | $6.6 | $372.46 |
| Effect of exchange rate | -$0.09 | -$0.11 | $0.82 | $0.72 |
| Change in cash and equivalents | -$72.07 | $40.64 | -$76.57 | $123.02 |
News
Fundamentals
| Market cap | $675.74M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 68.39M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.30 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.11 |
| Quick ratio | N/A |